Meng J, Wang ZG, Zhao X, Wang Y, Chen DY, Liu DL, Ji CC, Wang TF, Zhang LM, Bai HX, Li BY, Liu Y, Wang L, Yu WG, Yin ZT. Silica nanoparticle design for colorectal cancer treatment: Recent progress and clinical potential. World J Clin Oncol 2024; 15(6): 667-673 [PMID: 38946830 DOI: 10.5306/wjco.v15.i6.667]
Corresponding Author of This Article
Zhi-Tao Yin, MM, Chief Physician, Department of Anorectal Disease, Shenyang Coloproctology Hospital, No. 9 Nanjing North Street, Heping District, Shenyang 110000, Liaoning Province, China. yinzitao@163.com
Research Domain of This Article
Engineering, Biomedical
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jun 24, 2024; 15(6): 667-673 Published online Jun 24, 2024. doi: 10.5306/wjco.v15.i6.667
Silica nanoparticle design for colorectal cancer treatment: Recent progress and clinical potential
Jin Meng, Zhi-Gang Wang, Xiu Zhao, Ying Wang, De-Yu Chen, De-Long Liu, Cheng-Chun Ji, Tian-Fu Wang, Li-Mei Zhang, Hai-Xia Bai, Bo-Yang Li, Yuan Liu, Lei Wang, Wei-Gang Yu, Zhi-Tao Yin
Jin Meng, Zhi-Gang Wang, Xiu Zhao, De-Yu Chen, De-Long Liu, Cheng-Chun Ji, Tian-Fu Wang, Hai-Xia Bai, Bo-Yang Li, Yuan Liu, Lei Wang, Wei-Gang Yu, Zhi-Tao Yin, Department of Anorectal Disease, Shenyang Coloproctology Hospital, Shenyang 110000, Liaoning Province, China
Ying Wang, Acupuncture and Tuina College, Liaoning University of Traditional Chinese Medicine, Shenyang 110032, Liaoning Province, China
Li-Mei Zhang, Department of Neurology, Central Hospital of Dalian University of Technology, Dalian 116001, Liaoning Province, China
Author contributions: Yin ZT designed the study; Jin M wrote the paper; Wang ZG, Zhao X, Wang Y, Chen DY, Liu DL, Ji CC, Wang TF, Zhang LM, Ba HX, Li BY, Liu Y, Wang L, Yu WG collected and collated literature; All authors read and agreed the final manuscript.
Supported byThe Natural Science Foundation of Liaoning Province, No. 2022-MS-435; and Shenyang Science and Technology Plan Project, No. 22-321-33-79.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhi-Tao Yin, MM, Chief Physician, Department of Anorectal Disease, Shenyang Coloproctology Hospital, No. 9 Nanjing North Street, Heping District, Shenyang 110000, Liaoning Province, China. yinzitao@163.com
Received: December 9, 2023 Revised: March 18, 2024 Accepted: April 24, 2024 Published online: June 24, 2024 Processing time: 198 Days and 0.7 Hours
Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide and the second most common cause of cancer death. Nanotherapies are able to selectively target the delivery of cancer therapeutics, thus improving overall antitumor efficiency and reducing conventional chemotherapy side effects. Mesoporous silica nanoparticles (MSNs) have attracted the attention of many researchers due to their remarkable advantages and biosafety. We offer insights into the recent advances of MSNs in CRC treatment and their potential clinical application value.
Core Tip: Chemotherapy is the main treatment strategy for cancer. Despite the rapid development of medicine, conventional chemotherapy has some limitations. Mesoporous silica nanoparticles (MSNs) which can increase solubility, prolong the circulation time and reduce toxicity are already in use today, and show great promise in clinical development. This is due to their favorable properties as a nanocarrier, such as high surface area, tailorable pore sizes, controllable particle sizes and shapes, and dual-functional surfaces (exterior and interior). MSNs based therapies have remarkable benefits in both in vitro and in vivo testing. These nanosystems may lead to major advances in individualized treatment and have great potential for clinical translation.
